About us

EMUNO is run by a highly motivated team who combines in-depth experience in immunology, science, pharma and business.

We are all passionate to improve patients' lives by controlling immunity.

MANAGEMENT TEAM

Dr. Dipl.-Pharm. Emilia Neuwirt

Co-Founder & Chief Executive Officer

Emilia is an approbated pharmacist with more than 7 years of practical experience in public and hospital-associated pharmacies as well as a strong research background with specialisation in immuno-pharmacology and early-stage drug development. This provides her with a comprehensive understanding of pharmaceutical practices in different settings. She studied pharmacy in Freiburg and obtained a postgraduate diploma in pharmaceutical sciences at ETH Zurich, followed by a PhD in innate immunity and metabolism at the University of Freiburg. Emilia combines a creative, entrepreneurial mind with a deep scientific understanding and is the driving force behind EMUNO.

Prof. Dr. Olaf Groß

Co-Founder & Chief Scientific Officer

Olaf is an internationally renowned expert in the field of innate immunity, immuno-metabolism, cell death, and immuno-oncology research, working at top-level international research institutions. His seminal works include the discovery of new, protective innate immune pathways, and of intricate connections between mitochondria and the inflammasome. Olaf has 20+ years of research experience with relevance to the therapeutic control of immune responses with a special focus on the modulation of innate immunity by novel and established drugs, relevant to EMTs development pipeline. He has previously received two highly respected ERC research grants and is or has been partner in multiple (inter-)national collaborative research programs.

Dr. med. Andreas Vogt

Co-Founder & Chief Financial & Strategy Officer

Andreas is an internationally experienced physician, advisor, entrepreneur and investor with 25+ years of expertise in the healthcare and pharmaceutical industry. After working as a trauma surgeon and in the management team of a privately owned hospital chain, he held several leadership positions at Roland Berger and Deloitte consulting. Subsequently he acted as managing director and head of the EMEA healthcare & life science practice at AlixPartners. During his career Andreas has supported >15 life science start-ups, assuming various roles including CEO and CFO, and has successfully led >20 M&A transactions projects in this field.